Alnylam to move away from service-based research as Novartis cuts loose
This article was originally published in Scrip
Executive Summary
The five-year long RNAi-based research collaboration between Alnylam Pharmaceuticals and Novartis has come to an end, with the result that Alnylam is restructuring its operations "from a position of strength" with the intention of moving away from service-based research towards "higher value activities such as advancing our own pipeline", said chief executive Dr John Maraganore.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.